The secret ally: immunostimulation by anticancer drugs (Q37981038)

26 August 2017

title

The secret ally: immunostimulation by anticancer drugs (English)

1 reference

26 August 2017

2

Laura Senovilla

0 references

Laurence Zitvogel

series ordinal

3

object named as

Laurence Zitvogel

0 references

Guido Kroemer

series ordinal

4

object named as

Guido Kroemer

0 references

Lorenzo Galluzzi

series ordinal

1

object named as

Lorenzo Galluzzi

0 references

language of work or name

1 reference

3 February 2012

1 reference

Nature Reviews Drug Discovery

26 August 2017

published in

1 reference

26 August 2017

volume

11

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

215-233

1 reference

Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product

26 August 2017

cites work

1 reference

Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation

31 March 2020

1 reference

Timeline: Chemotherapy and the war on cancer.

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

31 March 2020

1 reference

Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome

31 March 2020

1 reference

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

31 March 2020

1 reference

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

31 March 2020

1 reference

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

31 March 2020

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

31 March 2020

1 reference

31 March 2020

Erlotinib hydrochloride

1 reference

31 March 2020

1 reference

The role of tumor stroma in the interaction between tumor and immune system

31 March 2020

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

31 March 2020

1 reference

Immunological aspects of cancer chemotherapy

31 March 2020

1 reference

Personalized medicine in oncology: the future is now.

31 March 2020

1 reference

Immune parameters affecting the efficacy of chemotherapeutic regimens

31 March 2020

1 reference

Stromal gene signatures in large-B-cell lymphomas

31 March 2020

1 reference

Dacarbazine Promotes Stromal Remodeling and Lymphocyte Infiltration in Cutaneous Melanoma Lesions

31 March 2020

1 reference

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome

31 March 2020

1 reference

Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma

31 March 2020

1 reference

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

31 March 2020

1 reference

Multifactorial approach to predicting resistance to anthracyclines

31 March 2020

1 reference

Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

31 March 2020

1 reference

Macrophage diversity enhances tumor progression and metastasis

31 March 2020

1 reference

Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma

31 March 2020

1 reference

Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma.

31 March 2020

1 reference

Prognostic significance of macrophage infiltration in leiomyosarcomas.

31 March 2020

1 reference

High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection.

31 March 2020

1 reference

Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma

31 March 2020

1 reference

Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer

31 March 2020

1 reference

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

31 March 2020

1 reference

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

31 March 2020

1 reference

Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer

31 March 2020

1 reference

Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation

31 March 2020

1 reference

Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients

31 March 2020

1 reference

Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer

31 March 2020

1 reference

Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients

31 March 2020

1 reference

Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy

31 March 2020

1 reference

Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer

31 March 2020

1 reference

Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy

31 March 2020

1 reference

Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma.

31 March 2020

1 reference

Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients.

31 March 2020

1 reference

Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma

31 March 2020

1 reference

Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease

31 March 2020

1 reference

Circulating antibodies to carcinoembryonic antigen related to improved recurrence-free survival of patients with colorectal carcinoma

31 March 2020

1 reference

Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk

31 March 2020

1 reference

AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma

31 March 2020

1 reference

Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer

31 March 2020

1 reference

High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome.

31 March 2020

1 reference

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

31 March 2020

1 reference

Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival

31 March 2020

1 reference

Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma

31 March 2020

1 reference

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis

31 March 2020

1 reference

Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms

31 March 2020

1 reference

Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer

31 March 2020

1 reference

Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial.

31 March 2020

1 reference

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

31 March 2020

1 reference

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

31 March 2020

1 reference

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

31 March 2020

1 reference

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

31 March 2020

1 reference

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

31 March 2020

1 reference

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

31 March 2020

1 reference

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

31 March 2020

1 reference

Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.

31 March 2020

1 reference

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

31 March 2020

1 reference

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

31 March 2020

1 reference

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

31 March 2020

1 reference

Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells.

31 March 2020

1 reference

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

31 March 2020

1 reference

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

31 March 2020

1 reference

Cyclophosphamide induces differentiation of Th17 cells in cancer patients

31 March 2020

1 reference

Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis

31 March 2020

1 reference

DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity

31 March 2020

1 reference

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

31 March 2020

1 reference

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

31 March 2020

1 reference

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

31 March 2020

1 reference

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy

31 March 2020

1 reference

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors

31 March 2020

1 reference

Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells

31 March 2020

1 reference

Immunogenic death of colon cancer cells treated with oxaliplatin

31 March 2020

1 reference

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

31 March 2020

1 reference

Calreticulin exposure dictates the immunogenicity of cancer cell death

31 March 2020

1 reference

Mitotic catastrophe: a mechanism for avoiding genomic instability.

31 March 2020

1 reference

CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4.

31 March 2020

1 reference

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

31 March 2020

1 reference

A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

31 March 2020

1 reference

Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells

31 March 2020

1 reference

Chemotherapy Induces Macrophage Chemoattractant Protein-1 Production in Ovarian Cancer

31 March 2020

1 reference

Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression

31 March 2020

1 reference

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

31 March 2020

1 reference

Bystander effect of vinorelbine alters antitumor immune response.

31 March 2020

1 reference

31 March 2020

Novel antifolate drugs

1 reference

31 March 2020

1 reference

Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis

31 March 2020

1 reference

Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations

31 March 2020

1 reference

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects

31 March 2020

1 reference

Cardiac side-effects of cancer chemotherapy

31 March 2020

1 reference

Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer

31 March 2020

1 reference

Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.

31 March 2020

1 reference

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

31 March 2020

1 reference

Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.

31 March 2020

1 reference

Gefitinib induces myeloid differentiation of acute myeloid leukemia

31 March 2020

1 reference

Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes

31 March 2020

1 reference

Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody.

31 March 2020

1 reference

Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway

31 March 2020

1 reference

Development and dynamics of robust T-cell responses to CML under imatinib treatment

31 March 2020

1 reference

Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia

31 March 2020

1 reference

Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors

31 March 2020

1 reference

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

31 March 2020

1 reference

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia

31 March 2020

1 reference

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

31 March 2020

1 reference

Modulation of T-effector function by imatinib at the level of cytokine secretion

31 March 2020

1 reference

Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.

31 March 2020

1 reference

A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients

31 March 2020

1 reference

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

31 March 2020

1 reference

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

31 March 2020

1 reference

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

31 March 2020

1 reference

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

31 March 2020

1 reference

Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice

31 March 2020

1 reference

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

31 March 2020

1 reference

Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells

31 March 2020

1 reference

Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

31 March 2020

1 reference

Profound inhibition of antigen-specific T-cell effector functions by dasatinib

31 March 2020

1 reference

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

31 March 2020

1 reference

Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo

31 March 2020

1 reference

Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo

31 March 2020

1 reference

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

31 March 2020

1 reference

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

31 March 2020

1 reference

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

31 March 2020

1 reference

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

31 March 2020

1 reference

Proteasome inhibition suppresses essential immune functions of human CD4+ T cells

31 March 2020

1 reference

The proteasome inhibitor bortezomib enhances the susceptibility to viral infection

31 March 2020

1 reference

Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib

31 March 2020

1 reference

Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.

31 March 2020

1 reference

Targeting the phosphoinositide 3-kinase pathway in cancer

31 March 2020

1 reference

The role of PI3K in immune cells

31 March 2020

1 reference

BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs

31 March 2020

1 reference

Monoclonal antibodies: versatile platforms for cancer immunotherapy

31 March 2020

1 reference

Molecular mechanisms of the antitumor effects of anti-CD20 antibodies

31 March 2020

1 reference

Complement regulators and inhibitory proteins

31 March 2020

1 reference

Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients

31 March 2020

1 reference

Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcgammaRs on human dendritic cells

31 March 2020

1 reference

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

31 March 2020

1 reference

Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

31 March 2020

1 reference

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

31 March 2020

1 reference

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

31 March 2020

1 reference

Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab

31 March 2020

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

31 March 2020

1 reference

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

31 March 2020

1 reference

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

31 March 2020

1 reference

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells

31 March 2020

1 reference

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

31 March 2020

1 reference

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

31 March 2020

1 reference

mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment

31 March 2020

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

Role of IL-1 receptor-associated kinase-M (IRAK-M) in priming of immune and inflammatory responses by nitrogen bisphosphonates

31 March 2020

1 reference

Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients

31 March 2020

1 reference

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer

31 March 2020

1 reference

IAP inhibitors enhance co-stimulation to promote tumor immunity

31 March 2020

1 reference

Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells

31 March 2020

1 reference

Cancer immunotherapy--revisited

31 March 2020

1 reference

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

31 March 2020

1 reference

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

31 March 2020

1 reference

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement

31 March 2020

1 reference

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.

31 March 2020

1 reference

WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase

31 March 2020

1 reference

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice.

31 March 2020

1 reference

Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.

31 March 2020

1 reference

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

31 March 2020

1 reference

Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.

31 March 2020

1 reference

Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.

31 March 2020

1 reference

Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients

31 March 2020

1 reference

Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells

31 March 2020

1 reference

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

31 March 2020

1 reference

Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients

31 March 2020

1 reference

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

31 March 2020

1 reference

Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells

31 March 2020

1 reference

Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer

31 March 2020

1 reference

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

31 March 2020

1 reference

CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice

31 March 2020

1 reference

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines

31 March 2020

1 reference

Factors regulating apoptosis and homeostasis of CD4+ CD25(high) FOXP3+ regulatory T cells are new therapeutic targets

31 March 2020

1 reference

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

31 March 2020

1 reference

Stattic: a small-molecule inhibitor of STAT3 activation and dimerization

31 March 2020

1 reference

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha

31 March 2020

1 reference

Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.

31 March 2020

1 reference

Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase

31 March 2020

1 reference

Decoding cell death signals in inflammation and immunity

31 March 2020

1 reference

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

31 March 2020

1 reference

CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation

31 March 2020

1 reference

The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing

31 March 2020

1 reference

Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited

31 March 2020

1 reference

Drug interactions in cancer therapy

31 March 2020

1 reference

How the glucocorticoids suppress immunity

31 March 2020

1 reference

Cimetidine: an anticancer drug?

31 March 2020

1 reference

Tumor cell metabolism: cancer's Achilles' heel

31 March 2020

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

31 March 2020

1 reference

Oncogenes and tumour suppressors take on centrosomes

31 March 2020

1 reference

Inflammation and necrosis promote tumour growth

31 March 2020

1 reference

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

Oncosuppressive functions of autophagy

31 March 2020

1 reference

Role of autophagy in cancer

31 March 2020

1 reference

Friends or foes - bipolar effects of the tumour stroma in cancer

31 March 2020

1 reference

Immunogenic and tolerogenic cell death

31 March 2020

1 reference

The immunogenicity of tumor cell death

31 March 2020

1 reference

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

31 March 2020

1 reference

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

31 March 2020

1 reference

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

31 March 2020

1 reference

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death

31 March 2020

1 reference

Chemotherapy induces ATP release from tumor cells

31 March 2020

1 reference

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice

31 March 2020

1 reference

Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis

31 March 2020

1 reference

VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling

31 March 2020

1 reference

Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells

31 March 2020

1 reference

12 December 2020

CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity

1 reference

12 December 2020

FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.

1 reference

12 December 2020

The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.

1 reference

12 December 2020

Infiltration of CD14-positive macrophages at the invasive front indicates a favorable prognosis in colorectal cancer patients with lymph node metastasis

1 reference

12 December 2020

Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.

1 reference

12 December 2020

Dendritic cell counts and their subsets during treatment of multiple myeloma

1 reference

12 December 2020

A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma.

1 reference

12 December 2020

Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.

1 reference

12 December 2020

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

1 reference

12 December 2020

Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma

1 reference

12 December 2020

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3626

1 reference

Dimensions Publication ID

26 August 2017

1014015173

0 references

1 reference